论文部分内容阅读
目的观察虫草多糖是否具有抗过敏性哮喘的作用。方法建立小鼠哮喘模型,第0,14天,分别腹腔注射OVA及其佐剂,自21 d时开始雾化吸入OVA一次,连续14 d,吸入OVA前0.5 h,观察组予虫草多糖100 mg.kg 1灌胃,阳性药物腹腔注射地塞米松。最后一次OVA雾化吸入后12 h进行气道高反应实验,之后收集支气管灌洗液进行细胞计数、分类、ELISA和RT-PCR检测,取左下肺组织做病理及免疫组化,观察肺组织炎症改变。结果①哮喘组气道反应性较正常组显著增高,虫草多糖治疗组气道反应性显著降低(P<0.05)。②病理组织分析哮喘组支气管和小血管周围显示明显的嗜酸性粒细胞浸润,支气管黏液分泌增加;虫草多糖治疗组支气管和小血管嗜酸性粒细胞浸润程度明显减轻,支气管黏液分泌减少。③哮喘组BALF中出现大量嗜酸性粒细胞,虫草多糖治疗组较哮喘组嗜酸性粒细胞明显减少(P<0.05)。④哮喘组支气管灌洗液中IL-4、IL-5、IL-13较正常组显著增加,虫草多糖治疗组较哮喘组明显降低(P<0.05)。⑤哮喘组肺组织中IL-4、IL-5、IL-13 mRNA表达增加,虫草多糖治疗组较哮喘组表达降低。结论虫草多糖治疗可在一定程度上减轻哮喘小鼠的气道嗜酸性粒细胞炎症及粘痰蛋白的分泌。
Objective To observe whether Cordyceps polysaccharide has anti-allergic asthma effect. Methods The mice model of asthma was established. On the 0th and the 14th day, OVA and its adjuvant were injected intraperitoneally. OVA was inhaled once every 21 days for 14 consecutive days and 0.5 h before OVA inhalation. The observation group received 100 mg .kg 1 gavage, positive drug intraperitoneal injection of dexamethasone. The bronchoalveolar lavage fluid was collected for cell counting, classification, ELISA and RT-PCR detection 12 h after the last inhalation of OVA inhalation, then the left lower lung tissue was taken for pathology and immunohistochemistry to observe the lung inflammation change. Results ① The airway responsiveness in asthma group was significantly higher than that in the normal group, but the airway responsiveness in the treated group was significantly decreased (P <0.05). ② Pathological analysis of bronchial and small blood vessels around the asthma group showed obvious eosinophil infiltration, bronchial mucus secretion increased; Cordyceps polysaccharide treatment of bronchial and small vessel eosinophil infiltration significantly reduced, bronchial mucus secretion decreased. (3) A large number of eosinophils were found in the BALF of asthmatic group, while eosinophils in the treatment group of Cordyceps reduced significantly (P <0.05). (4) IL-4, IL-5 and IL-13 in bronchoalveolar lavage fluid in asthma group were significantly increased compared with those in normal group, while those in the treatment group with Cordyceps polysaccharide were significantly lower than those in asthma group (P <0.05). (5) The expression of IL-4, IL-5 and IL-13 mRNA in lung tissue of asthmatic group increased, and the expression of IL-5 and IL-13 mRNA in asthmatic group was lower than that in asthmatic group. Conclusion Cordyceps polysaccharide can relieve airway eosinophilic inflammation and secretion of mucolytic protein to a certain extent in asthmatic mice.